# Isolated Limb Infusion Chemotherapy With Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma

> **NCT01531244** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Washington University School of Medicine**

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** dactinomycin
- **DRUG:** melphalan
- **BIOLOGICAL:** Conditionally replicative adenovirus 3/5-delta

## Key facts

- **NCT ID:** NCT01531244
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-12
- **Primary completion:** 2016-02
- **Final completion:** 2016-02
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2014-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01531244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01531244, "Isolated Limb Infusion Chemotherapy With Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01531244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*